Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

CCA masthead new1

Clinical Cardiology Alert – November 1, 2019

November 1, 2019

View Archives Issues

  • When and How to Stop Dual Antiplatelet Therapy After PCI

    Among patients with high-risk percutaneous coronary intervention who had completed three months of dual antiplatelet therapy with ticagrelor, patients who were randomized to ticagrelor alone experienced similar ischemic outcomes and a lower risk of bleeding at one year compared with those maintained on ticagrelor and aspirin.

  • Predicting Chemotherapy Cardiotoxicity

    Administering trastuzumab after a course of anthracycline therapy for breast cancer can result in cardiac toxicity. Serial echocardiograms in this study showed that a lower initial left ventricular ejection fraction before anthracycline therapy and the amount of decrease in ejection fraction after the anthracycline course are predictive of subsequent trastuzumab cardiac toxicity.

  • Planning Therapy for Severe Tricuspid Regurgitation

    A retrospective study of moderate to severe secondary tricuspid valve regurgitation showed that right ventricular systolic dysfunction (but not dilatation alone) is predictive of all-cause mortality.

  • Safety of Carvedilol for Cocaine Users

    The use of beta-blockers in cocaine users is controversial, and there are few data on their use in cocaine-associated heart failure. This prospective, observational, registry study of cocaine-associated heart failure patients showed that carvedilol is safe and effective in such patients.

  • Cardiac Arrest in Takotsubo Syndrome

    Investigators sought to determine whether secondary prevention interventions could reduce the mortality rate of takotsubo patients with cardiac arrest.